| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Enzyme Inhibitors | 11 | 2025 | 458 | 2.080 |
Why?
|
| Antineoplastic Agents | 17 | 2025 | 1019 | 1.970 |
Why?
|
| DEAD-box RNA Helicases | 2 | 2025 | 25 | 1.800 |
Why?
|
| Prostatic Neoplasms | 14 | 2022 | 1092 | 1.720 |
Why?
|
| Naphthoquinones | 5 | 2020 | 41 | 1.570 |
Why?
|
| Apoptosis | 11 | 2025 | 1568 | 1.330 |
Why?
|
| Benzamides | 6 | 2018 | 81 | 1.230 |
Why?
|
| Receptors, Calcitriol | 5 | 2024 | 69 | 1.120 |
Why?
|
| Cell Line, Tumor | 31 | 2025 | 2676 | 1.060 |
Why?
|
| Pyridones | 6 | 2018 | 50 | 1.020 |
Why?
|
| DNA Mismatch Repair | 1 | 2025 | 28 | 0.880 |
Why?
|
| Microsatellite Instability | 1 | 2025 | 48 | 0.880 |
Why?
|
| MicroRNAs | 4 | 2024 | 518 | 0.850 |
Why?
|
| Humans | 75 | 2026 | 43102 | 0.840 |
Why?
|
| Parkinson Disease | 3 | 2022 | 210 | 0.820 |
Why?
|
| Neoplasms | 4 | 2026 | 1377 | 0.800 |
Why?
|
| Vitamin D | 3 | 2022 | 196 | 0.770 |
Why?
|
| Breast Neoplasms | 6 | 2025 | 1723 | 0.760 |
Why?
|
| Exercise | 7 | 2023 | 692 | 0.760 |
Why?
|
| Cell Proliferation | 16 | 2025 | 1455 | 0.700 |
Why?
|
| Isoquinolines | 4 | 2022 | 55 | 0.650 |
Why?
|
| Tamoxifen | 1 | 2020 | 69 | 0.640 |
Why?
|
| Neuroprotective Agents | 4 | 2022 | 269 | 0.620 |
Why?
|
| Nicotine | 5 | 2020 | 302 | 0.620 |
Why?
|
| Antiparkinson Agents | 1 | 2019 | 14 | 0.610 |
Why?
|
| Nerve Growth Factors | 1 | 2019 | 34 | 0.600 |
Why?
|
| Colorectal Neoplasms | 1 | 2025 | 512 | 0.590 |
Why?
|
| Antidepressive Agents | 1 | 2019 | 65 | 0.590 |
Why?
|
| Emetine | 2 | 2015 | 14 | 0.580 |
Why?
|
| Methyltransferases | 6 | 2019 | 68 | 0.550 |
Why?
|
| Xenograft Model Antitumor Assays | 7 | 2025 | 347 | 0.530 |
Why?
|
| Social Support | 1 | 2020 | 445 | 0.520 |
Why?
|
| S-Adenosylhomocysteine | 2 | 2019 | 11 | 0.520 |
Why?
|
| Wasps | 3 | 2024 | 27 | 0.520 |
Why?
|
| Methylation | 12 | 2019 | 119 | 0.510 |
Why?
|
| Histones | 7 | 2017 | 197 | 0.500 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 2017 | 465 | 0.500 |
Why?
|
| Depression | 3 | 2022 | 863 | 0.490 |
Why?
|
| Drug Evaluation, Preclinical | 2 | 2016 | 127 | 0.490 |
Why?
|
| Polymerase Chain Reaction | 1 | 2017 | 455 | 0.490 |
Why?
|
| RNA | 1 | 2018 | 266 | 0.480 |
Why?
|
| Mental Disorders | 1 | 2020 | 392 | 0.480 |
Why?
|
| Enzyme Assays | 1 | 2016 | 13 | 0.480 |
Why?
|
| Ditiocarb | 1 | 2015 | 4 | 0.470 |
Why?
|
| Lymphoma, B-Cell | 2 | 2018 | 28 | 0.470 |
Why?
|
| Cell Survival | 7 | 2020 | 945 | 0.460 |
Why?
|
| Cadmium | 2 | 2025 | 56 | 0.450 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2026 | 375 | 0.450 |
Why?
|
| Suntan | 1 | 2014 | 5 | 0.450 |
Why?
|
| Inhibitory Concentration 50 | 6 | 2020 | 99 | 0.440 |
Why?
|
| Histone-Lysine N-Methyltransferase | 6 | 2018 | 31 | 0.440 |
Why?
|
| Polymorphism, Single Nucleotide | 5 | 2024 | 863 | 0.430 |
Why?
|
| Receptors, Estrogen | 2 | 2025 | 183 | 0.420 |
Why?
|
| Lysine | 4 | 2017 | 119 | 0.390 |
Why?
|
| Neoplasm Proteins | 2 | 2025 | 228 | 0.390 |
Why?
|
| Animals | 23 | 2025 | 16992 | 0.380 |
Why?
|
| Point Mutation | 3 | 2014 | 98 | 0.370 |
Why?
|
| Calcium | 2 | 2025 | 491 | 0.370 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2024 | 734 | 0.370 |
Why?
|
| Pyrimidines | 3 | 2017 | 139 | 0.350 |
Why?
|
| Male | 27 | 2025 | 23409 | 0.350 |
Why?
|
| Preoperative Care | 3 | 2026 | 32 | 0.350 |
Why?
|
| Schizophrenia | 2 | 2023 | 93 | 0.340 |
Why?
|
| Bipolar Disorder | 2 | 2023 | 84 | 0.340 |
Why?
|
| Neuroblastoma | 4 | 2022 | 136 | 0.330 |
Why?
|
| Benzimidazoles | 3 | 2017 | 43 | 0.330 |
Why?
|
| Biphenyl Compounds | 7 | 2018 | 53 | 0.330 |
Why?
|
| Female | 24 | 2025 | 24698 | 0.330 |
Why?
|
| Androgens | 2 | 2011 | 106 | 0.330 |
Why?
|
| DNA Methylation | 4 | 2025 | 403 | 0.330 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2010 | 19 | 0.320 |
Why?
|
| Promoter Regions, Genetic | 3 | 2025 | 526 | 0.310 |
Why?
|
| Quality of Life | 3 | 2025 | 616 | 0.310 |
Why?
|
| Crystallography, X-Ray | 5 | 2025 | 280 | 0.310 |
Why?
|
| Mice | 11 | 2025 | 6644 | 0.310 |
Why?
|
| Structure-Activity Relationship | 6 | 2025 | 506 | 0.300 |
Why?
|
| Cell Cycle | 6 | 2014 | 346 | 0.300 |
Why?
|
| Neurotoxins | 2 | 2007 | 57 | 0.290 |
Why?
|
| Adult | 14 | 2025 | 13872 | 0.280 |
Why?
|
| Consensus | 2 | 2026 | 48 | 0.270 |
Why?
|
| Protein-Arginine N-Methyltransferases | 2 | 2019 | 7 | 0.270 |
Why?
|
| Estrogen Receptor alpha | 2 | 2025 | 121 | 0.270 |
Why?
|
| Ultraviolet Rays | 2 | 2020 | 118 | 0.270 |
Why?
|
| DNA-Binding Proteins | 1 | 2010 | 561 | 0.260 |
Why?
|
| Research Design | 2 | 2026 | 385 | 0.260 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 3 | 2017 | 8 | 0.250 |
Why?
|
| Drug Synergism | 4 | 2020 | 195 | 0.250 |
Why?
|
| Mice, Nude | 3 | 2025 | 408 | 0.250 |
Why?
|
| Drug Discovery | 2 | 2025 | 108 | 0.250 |
Why?
|
| Kinetics | 4 | 2016 | 695 | 0.240 |
Why?
|
| Ethanol | 3 | 2021 | 224 | 0.240 |
Why?
|
| Checklist | 1 | 2026 | 17 | 0.240 |
Why?
|
| Exercise Therapy | 2 | 2024 | 87 | 0.240 |
Why?
|
| Middle Aged | 16 | 2025 | 12222 | 0.240 |
Why?
|
| RNA, Messenger | 5 | 2021 | 1271 | 0.240 |
Why?
|
| Pluripotent Stem Cells | 1 | 2025 | 31 | 0.240 |
Why?
|
| Morpholines | 5 | 2018 | 72 | 0.240 |
Why?
|
| Transcription Factors | 1 | 2010 | 735 | 0.240 |
Why?
|
| Allosteric Regulation | 1 | 2025 | 27 | 0.230 |
Why?
|
| Exoribonucleases | 1 | 2025 | 10 | 0.230 |
Why?
|
| Fibroadenoma | 1 | 2025 | 4 | 0.230 |
Why?
|
| Small Molecule Libraries | 3 | 2018 | 62 | 0.230 |
Why?
|
| Leukemia | 2 | 2017 | 54 | 0.220 |
Why?
|
| Aspartic Acid Endopeptidases | 2 | 2011 | 19 | 0.220 |
Why?
|
| Dose-Response Relationship, Drug | 8 | 2018 | 1124 | 0.220 |
Why?
|
| Administration, Oral | 1 | 2025 | 260 | 0.210 |
Why?
|
| Gene Expression Regulation, Neoplastic | 5 | 2021 | 968 | 0.210 |
Why?
|
| Lymphoma, Non-Hodgkin | 2 | 2014 | 40 | 0.210 |
Why?
|
| Aged | 11 | 2025 | 8214 | 0.200 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2025 | 133 | 0.200 |
Why?
|
| Parasites | 1 | 2023 | 38 | 0.200 |
Why?
|
| Drosophilidae | 1 | 2022 | 1 | 0.190 |
Why?
|
| Blotting, Western | 3 | 2010 | 883 | 0.180 |
Why?
|
| Sports | 1 | 2023 | 55 | 0.180 |
Why?
|
| Postoperative Complications | 1 | 2024 | 263 | 0.180 |
Why?
|
| Cell Death | 6 | 2020 | 278 | 0.180 |
Why?
|
| Prognosis | 3 | 2021 | 861 | 0.180 |
Why?
|
| Butyric Acid | 1 | 2021 | 19 | 0.180 |
Why?
|
| Recombinant Proteins | 1 | 2003 | 518 | 0.170 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2021 | 38 | 0.170 |
Why?
|
| Neurodegenerative Diseases | 1 | 2022 | 141 | 0.170 |
Why?
|
| Severity of Illness Index | 2 | 2020 | 719 | 0.170 |
Why?
|
| Sunbathing | 1 | 2020 | 8 | 0.170 |
Why?
|
| Binding Sites | 3 | 2016 | 671 | 0.170 |
Why?
|
| Qualitative Research | 2 | 2021 | 574 | 0.170 |
Why?
|
| Butyrates | 1 | 2020 | 34 | 0.160 |
Why?
|
| Risk | 3 | 2015 | 287 | 0.160 |
Why?
|
| Mass Spectrometry | 2 | 2019 | 280 | 0.160 |
Why?
|
| Gene Expression Profiling | 4 | 2021 | 704 | 0.160 |
Why?
|
| Purine-Nucleoside Phosphorylase | 1 | 2019 | 2 | 0.150 |
Why?
|
| Gene Rearrangement | 2 | 2017 | 17 | 0.150 |
Why?
|
| RNA Processing, Post-Transcriptional | 1 | 2019 | 31 | 0.150 |
Why?
|
| Psychotic Disorders | 1 | 2020 | 71 | 0.150 |
Why?
|
| Receptors, Nicotinic | 1 | 2020 | 114 | 0.150 |
Why?
|
| Lung Neoplasms | 1 | 2025 | 495 | 0.150 |
Why?
|
| Case-Control Studies | 5 | 2024 | 1285 | 0.150 |
Why?
|
| Dopamine | 3 | 2022 | 275 | 0.140 |
Why?
|
| Microfluidics | 1 | 2018 | 45 | 0.140 |
Why?
|
| CARD Signaling Adaptor Proteins | 1 | 2017 | 11 | 0.140 |
Why?
|
| Guanylate Cyclase | 1 | 2017 | 21 | 0.140 |
Why?
|
| Isoxazoles | 1 | 2017 | 15 | 0.140 |
Why?
|
| Amyloid Precursor Protein Secretases | 2 | 2011 | 35 | 0.140 |
Why?
|
| Spiro Compounds | 1 | 2017 | 16 | 0.140 |
Why?
|
| Reactive Oxygen Species | 1 | 2020 | 532 | 0.140 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2017 | 21 | 0.130 |
Why?
|
| Multiple Myeloma | 1 | 2017 | 48 | 0.130 |
Why?
|
| Prostate-Specific Antigen | 2 | 2015 | 147 | 0.130 |
Why?
|
| Catalysis | 2 | 2010 | 187 | 0.130 |
Why?
|
| Neoplasm Transplantation | 5 | 2017 | 129 | 0.130 |
Why?
|
| Pyrazoles | 1 | 2017 | 103 | 0.130 |
Why?
|
| Flow Cytometry | 2 | 2009 | 411 | 0.130 |
Why?
|
| Comorbidity | 1 | 2019 | 737 | 0.130 |
Why?
|
| Sarcoma, Synovial | 1 | 2016 | 2 | 0.130 |
Why?
|
| Delphi Technique | 2 | 2026 | 34 | 0.120 |
Why?
|
| Binding, Competitive | 1 | 2016 | 109 | 0.120 |
Why?
|
| Molecular Probes | 1 | 2015 | 23 | 0.120 |
Why?
|
| Lymphoma, Mantle-Cell | 1 | 2015 | 5 | 0.120 |
Why?
|
| Zanthoxylum | 1 | 2015 | 4 | 0.110 |
Why?
|
| Occupational Health | 1 | 2015 | 32 | 0.110 |
Why?
|
| Prostatic Hyperplasia | 1 | 2015 | 32 | 0.110 |
Why?
|
| Information Dissemination | 1 | 2015 | 66 | 0.110 |
Why?
|
| Sunlight | 1 | 2014 | 48 | 0.110 |
Why?
|
| Cockroaches | 1 | 2014 | 8 | 0.110 |
Why?
|
| Growth Inhibitors | 1 | 2014 | 29 | 0.110 |
Why?
|
| Protein Binding | 4 | 2019 | 1082 | 0.110 |
Why?
|
| Workplace | 1 | 2015 | 92 | 0.110 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2017 | 307 | 0.110 |
Why?
|
| Nucleus Accumbens | 2 | 2007 | 100 | 0.110 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2014 | 38 | 0.100 |
Why?
|
| Metabolomics | 1 | 2014 | 95 | 0.100 |
Why?
|
| Age Factors | 1 | 2017 | 1154 | 0.100 |
Why?
|
| Rhabdoid Tumor | 1 | 2013 | 5 | 0.100 |
Why?
|
| Smoking | 1 | 2020 | 1024 | 0.100 |
Why?
|
| Carrier Proteins | 1 | 2015 | 321 | 0.100 |
Why?
|
| Indazoles | 1 | 2012 | 12 | 0.100 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2014 | 220 | 0.090 |
Why?
|
| Lymphoma | 1 | 2012 | 41 | 0.090 |
Why?
|
| Eye Infections, Viral | 1 | 2012 | 4 | 0.090 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2012 | 44 | 0.090 |
Why?
|
| Leukemia, Biphenotypic, Acute | 1 | 2011 | 1 | 0.090 |
Why?
|
| Plant Extracts | 1 | 2015 | 302 | 0.090 |
Why?
|
| Diamines | 1 | 2011 | 8 | 0.090 |
Why?
|
| Benzoxazoles | 1 | 2011 | 10 | 0.090 |
Why?
|
| Oxazoles | 1 | 2011 | 19 | 0.080 |
Why?
|
| Models, Molecular | 4 | 2019 | 876 | 0.080 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2025 | 223 | 0.080 |
Why?
|
| Biomedical Research | 1 | 2015 | 502 | 0.080 |
Why?
|
| Immunoenzyme Techniques | 1 | 2010 | 114 | 0.080 |
Why?
|
| Molecular Structure | 3 | 2019 | 570 | 0.080 |
Why?
|
| Central Nervous System Depressants | 2 | 2007 | 42 | 0.080 |
Why?
|
| DNA Topoisomerases, Type I | 1 | 2009 | 9 | 0.070 |
Why?
|
| Phylogeny | 2 | 2023 | 769 | 0.070 |
Why?
|
| Nicotinic Agonists | 2 | 2007 | 88 | 0.070 |
Why?
|
| Catalytic Domain | 2 | 2014 | 118 | 0.070 |
Why?
|
| Drug Interactions | 2 | 2007 | 150 | 0.070 |
Why?
|
| RNA Interference | 2 | 2021 | 247 | 0.070 |
Why?
|
| Tumor Cells, Cultured | 1 | 2010 | 508 | 0.070 |
Why?
|
| Oxadiazoles | 1 | 2008 | 15 | 0.070 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2010 | 458 | 0.070 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 652 | 0.070 |
Why?
|
| Mice, SCID | 3 | 2014 | 158 | 0.070 |
Why?
|
| Signal Transduction | 3 | 2025 | 2157 | 0.070 |
Why?
|
| Drug Design | 3 | 2015 | 186 | 0.070 |
Why?
|
| Genotype | 2 | 2024 | 800 | 0.070 |
Why?
|
| Aged, 80 and over | 1 | 2014 | 2853 | 0.070 |
Why?
|
| Protein Structure, Tertiary | 2 | 2012 | 423 | 0.070 |
Why?
|
| Annexin A5 | 1 | 2007 | 27 | 0.070 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2008 | 159 | 0.070 |
Why?
|
| Retinoblastoma Protein | 1 | 2007 | 29 | 0.060 |
Why?
|
| Parkinsonian Disorders | 1 | 2007 | 42 | 0.060 |
Why?
|
| Bone Marrow Cells | 1 | 2007 | 79 | 0.060 |
Why?
|
| Cell Differentiation | 2 | 2025 | 638 | 0.060 |
Why?
|
| Sulfonamides | 1 | 2007 | 91 | 0.060 |
Why?
|
| Adenosine Triphosphate | 1 | 2007 | 206 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2008 | 299 | 0.060 |
Why?
|
| Time Factors | 2 | 2018 | 1857 | 0.060 |
Why?
|
| Tetrazolium Salts | 1 | 2005 | 36 | 0.060 |
Why?
|
| Conotoxins | 1 | 2005 | 20 | 0.060 |
Why?
|
| Rats | 5 | 2014 | 3735 | 0.060 |
Why?
|
| Thiazoles | 1 | 2005 | 76 | 0.060 |
Why?
|
| Glucagon | 1 | 2024 | 7 | 0.060 |
Why?
|
| Gene Expression Regulation, Leukemic | 2 | 2017 | 8 | 0.060 |
Why?
|
| Hep G2 Cells | 1 | 2024 | 63 | 0.050 |
Why?
|
| Hymenoptera | 1 | 2024 | 6 | 0.050 |
Why?
|
| Substrate Specificity | 2 | 2019 | 219 | 0.050 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2025 | 95 | 0.050 |
Why?
|
| Animal Structures | 1 | 2024 | 22 | 0.050 |
Why?
|
| Kenya | 1 | 2024 | 58 | 0.050 |
Why?
|
| Oncogene Proteins, Fusion | 2 | 2016 | 17 | 0.050 |
Why?
|
| Terminology as Topic | 1 | 2024 | 42 | 0.050 |
Why?
|
| Body Size | 1 | 2024 | 49 | 0.050 |
Why?
|
| Iran | 1 | 2024 | 202 | 0.050 |
Why?
|
| Organ Size | 1 | 2024 | 170 | 0.050 |
Why?
|
| European Union | 1 | 2023 | 6 | 0.050 |
Why?
|
| Scattering, Radiation | 1 | 2003 | 43 | 0.050 |
Why?
|
| Flavonols | 1 | 2022 | 19 | 0.050 |
Why?
|
| Molecular Dynamics Simulation | 1 | 2024 | 188 | 0.050 |
Why?
|
| CHO Cells | 1 | 2003 | 123 | 0.050 |
Why?
|
| Endopeptidases | 1 | 2003 | 64 | 0.050 |
Why?
|
| Glycosylation | 1 | 2003 | 113 | 0.050 |
Why?
|
| Acetic Acid | 1 | 2022 | 19 | 0.050 |
Why?
|
| Cricetinae | 1 | 2003 | 241 | 0.050 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2022 | 81 | 0.050 |
Why?
|
| Lipid Bilayers | 1 | 2003 | 57 | 0.050 |
Why?
|
| Disease Progression | 1 | 2025 | 667 | 0.050 |
Why?
|
| Light | 1 | 2003 | 185 | 0.050 |
Why?
|
| Drosophila | 1 | 2003 | 152 | 0.050 |
Why?
|
| Ventral Tegmental Area | 1 | 2002 | 49 | 0.040 |
Why?
|
| Ligands | 1 | 2003 | 388 | 0.040 |
Why?
|
| Rehabilitation | 1 | 2021 | 5 | 0.040 |
Why?
|
| Genomics | 1 | 2023 | 293 | 0.040 |
Why?
|
| ROC Curve | 1 | 2021 | 159 | 0.040 |
Why?
|
| Risk Factors | 2 | 2020 | 3994 | 0.040 |
Why?
|
| Organizational Policy | 1 | 2021 | 25 | 0.040 |
Why?
|
| Exercise Tolerance | 1 | 2021 | 22 | 0.040 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2017 | 1766 | 0.040 |
Why?
|
| Respiratory Tract Diseases | 1 | 2021 | 31 | 0.040 |
Why?
|
| Cell Membrane | 1 | 2003 | 403 | 0.040 |
Why?
|
| Receptors, Virus | 1 | 2020 | 23 | 0.040 |
Why?
|
| Prospective Studies | 1 | 2025 | 1600 | 0.040 |
Why?
|
| Alzheimer Disease | 2 | 2011 | 1001 | 0.040 |
Why?
|
| Immunohistochemistry | 1 | 2022 | 934 | 0.040 |
Why?
|
| Escherichia coli | 1 | 2003 | 460 | 0.040 |
Why?
|
| Cross-Sectional Studies | 2 | 2023 | 3156 | 0.040 |
Why?
|
| RNA Stability | 1 | 2019 | 28 | 0.040 |
Why?
|
| Peptides | 1 | 2003 | 372 | 0.040 |
Why?
|
| Adenosine | 1 | 2019 | 62 | 0.040 |
Why?
|
| Multiprotein Complexes | 1 | 2019 | 56 | 0.040 |
Why?
|
| Health Policy | 1 | 2021 | 184 | 0.040 |
Why?
|
| Cell Line | 1 | 2003 | 1410 | 0.040 |
Why?
|
| Molecular Conformation | 1 | 2019 | 155 | 0.040 |
Why?
|
| Computational Biology | 1 | 2021 | 327 | 0.040 |
Why?
|
| Alternative Splicing | 1 | 2019 | 94 | 0.040 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-3 | 1 | 2018 | 9 | 0.040 |
Why?
|
| Osteonectin | 1 | 2018 | 10 | 0.040 |
Why?
|
| Host-Pathogen Interactions | 1 | 2020 | 209 | 0.040 |
Why?
|
| Receptors, Retinoic Acid | 1 | 2018 | 27 | 0.040 |
Why?
|
| Mental Health | 1 | 2023 | 385 | 0.040 |
Why?
|
| Cell Size | 1 | 2018 | 46 | 0.040 |
Why?
|
| Maximum Tolerated Dose | 1 | 2018 | 11 | 0.040 |
Why?
|
| France | 1 | 2018 | 23 | 0.040 |
Why?
|
| Mutation | 2 | 2017 | 1177 | 0.030 |
Why?
|
| Lab-On-A-Chip Devices | 1 | 2018 | 38 | 0.030 |
Why?
|
| Genetic Markers | 1 | 2018 | 150 | 0.030 |
Why?
|
| Cadherins | 1 | 2018 | 102 | 0.030 |
Why?
|
| Receptors, Dopamine D2 | 1 | 2018 | 83 | 0.030 |
Why?
|
| HIV Infections | 1 | 2012 | 2586 | 0.030 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2019 | 300 | 0.030 |
Why?
|
| Adenine | 1 | 2017 | 46 | 0.030 |
Why?
|
| Lung | 1 | 2020 | 492 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2017 | 116 | 0.030 |
Why?
|
| Piperidines | 1 | 2017 | 83 | 0.030 |
Why?
|
| Telemedicine | 1 | 2021 | 234 | 0.030 |
Why?
|
| Adolescent | 2 | 2023 | 6081 | 0.030 |
Why?
|
| B-Lymphocytes | 1 | 2017 | 189 | 0.030 |
Why?
|
| Intellectual Property | 1 | 2015 | 2 | 0.030 |
Why?
|
| Trypsin Inhibitor, Kazal Pancreatic | 1 | 2015 | 4 | 0.030 |
Why?
|
| Interior Design and Furnishings | 1 | 2015 | 4 | 0.030 |
Why?
|
| snRNP Core Proteins | 1 | 2015 | 12 | 0.030 |
Why?
|
| Molecular Weight | 1 | 2015 | 168 | 0.030 |
Why?
|
| Mecamylamine | 2 | 2007 | 21 | 0.030 |
Why?
|
| Costs and Cost Analysis | 1 | 2015 | 60 | 0.030 |
Why?
|
| Mice, Inbred Strains | 1 | 2015 | 114 | 0.030 |
Why?
|
| Gene Expression Regulation | 1 | 2020 | 1070 | 0.030 |
Why?
|
| Posture | 1 | 2015 | 61 | 0.030 |
Why?
|
| Vincristine | 1 | 2014 | 14 | 0.030 |
Why?
|
| Prednisolone | 1 | 2014 | 16 | 0.030 |
Why?
|
| Nicotinic Antagonists | 2 | 2007 | 36 | 0.030 |
Why?
|
| Prednisone | 1 | 2014 | 31 | 0.030 |
Why?
|
| Receptors, Glucocorticoid | 1 | 2014 | 35 | 0.030 |
Why?
|
| Dipeptides | 1 | 2014 | 31 | 0.030 |
Why?
|
| Cyclophosphamide | 1 | 2014 | 59 | 0.030 |
Why?
|
| Dexamethasone | 1 | 2014 | 55 | 0.030 |
Why?
|
| NAD | 1 | 2014 | 45 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2016 | 694 | 0.030 |
Why?
|
| Metabolome | 1 | 2014 | 51 | 0.030 |
Why?
|
| Phytotherapy | 1 | 2015 | 75 | 0.030 |
Why?
|
| Random Allocation | 1 | 2014 | 147 | 0.030 |
Why?
|
| Cytokines | 1 | 2018 | 678 | 0.030 |
Why?
|
| Haplotypes | 1 | 2015 | 197 | 0.030 |
Why?
|
| Glucocorticoids | 1 | 2014 | 91 | 0.030 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2014 | 74 | 0.030 |
Why?
|
| Rats, Wistar | 2 | 2007 | 283 | 0.030 |
Why?
|
| Doxorubicin | 1 | 2014 | 97 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2015 | 223 | 0.030 |
Why?
|
| Amino Acids | 1 | 2014 | 148 | 0.030 |
Why?
|
| Glutathione | 1 | 2014 | 171 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2015 | 611 | 0.030 |
Why?
|
| Rats, Nude | 1 | 2013 | 6 | 0.030 |
Why?
|
| Internet | 1 | 2015 | 236 | 0.030 |
Why?
|
| Models, Biological | 1 | 2017 | 712 | 0.030 |
Why?
|
| Treatment Outcome | 1 | 2018 | 1604 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2014 | 290 | 0.030 |
Why?
|
| Energy Metabolism | 1 | 2014 | 187 | 0.030 |
Why?
|
| Oxidation-Reduction | 1 | 2014 | 457 | 0.020 |
Why?
|
| Plant Roots | 1 | 2015 | 180 | 0.020 |
Why?
|
| Nucleosides | 1 | 2012 | 30 | 0.020 |
Why?
|
| Pyridines | 1 | 2013 | 139 | 0.020 |
Why?
|
| Protein Conformation | 1 | 2013 | 416 | 0.020 |
Why?
|
| District of Columbia | 1 | 2012 | 80 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2015 | 863 | 0.020 |
Why?
|
| Ophthalmology | 1 | 2012 | 34 | 0.020 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2012 | 201 | 0.020 |
Why?
|
| Visual Acuity | 1 | 2012 | 111 | 0.020 |
Why?
|
| Phenotype | 1 | 2014 | 780 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2014 | 1542 | 0.020 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2012 | 229 | 0.020 |
Why?
|
| Epigenesis, Genetic | 1 | 2013 | 291 | 0.020 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2012 | 279 | 0.020 |
Why?
|
| Health Promotion | 1 | 2015 | 704 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2011 | 1035 | 0.020 |
Why?
|
| Microdialysis | 1 | 2007 | 18 | 0.020 |
Why?
|
| Extracellular Space | 1 | 2007 | 36 | 0.020 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2008 | 301 | 0.020 |
Why?
|
| Prevalence | 1 | 2012 | 1612 | 0.020 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2007 | 157 | 0.020 |
Why?
|
| United States | 1 | 2017 | 5205 | 0.020 |
Why?
|
| Drug Combinations | 1 | 2002 | 104 | 0.010 |
Why?
|
| Young Adult | 1 | 2012 | 5080 | 0.010 |
Why?
|